| J3245 | Injection, tildrakizumab, 1 mg | 4,800 | $110 | $528K |
| Q4257 | Relese, per square centimeter (add-on, list separately in addition to primary procedure) | 840 | $550 | $463.4K |
| Q4229 | Cogenex amniotic membrane, per square centimeter (add-on, list separately in addition to primary procedure) | 1,250 | $200 | $254.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 740 | $90 | $65.4K |
| 17110 | The provider destroys benign lesions using techniques such as chemosurgery, cryosurgery, electrosurgery, or others. This code reports the destruction of one to 14 lesions other than skin tags or… | 250 | $90 | $21.2K |
| 11102 | The provider biopsies a single skin lesion using a tangential (side–ways) approach; he shaves off the lesion or scoops it out with a knife or curette. | 230 | $70 | $15.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 90 | $130 | $11.3K |
| 15271 | The provider uses a skin substitute, such as an allograft or xenograft, to cover wounds on the patient’s trunk, arms, and/or legs up to an area of 100 cm2. This code covers up to the first 25 cm2. | 110 | $100 | $10.9K |
| 17000 | The provider destroys a premalignant lesion using techniques such as chemosurgery, cryosurgery, electrosurgery, or others. This code reports the destruction of the first or only lesion. | 270 | $40 | $9.7K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 70 | $100 | $7.2K |